cefepime and Bronchitis

Cefepime (Maxipime, Bristol-Myers Squibb), a 4th generation cephalosporin was used in the postoperative treatment of 121 patients of Anesthesiology and Intensive Care Unit of Neurosurgical Clinics. The patients were divided into groups by the risk factor of pyoseptic complications. The results were estimated by the number and nature of the complications such as increasing liquor neutrophilic cytosis, systemic inflammations and others. The findings (increasing liquor neutrophilic cytosis only in 2 patients and endobronchitis in 4 patients) and good tolerance of cefepime (Maxipime) were in favour of its use in a dose of 1 g administered intravenously dropwise during initial narcosis and in 12 hours as an efficient agent for perioperative prophylaxis in neurosurgical patients.

Topics: Anesthesia Department, Hospital; Antibiotic Prophylaxis; Bronchitis; Cefepime; Cephalosporins; Humans; Inflammation; Infusions, Intravenous; Intensive Care Units; Leukocyte Count; Nervous System Diseases; Neutrophils; Postoperative Complications; Surgery Department, Hospital; Treatment Outcome